Event

Conference on Retroviruses and Opportunistic Infection

The annual Conference on Retroviruses and Opportunistic Infections (CROI) is the premier HIV conference in the world and draws delegates from all over the globe. This year it is being held in Boston.

Dr. Ian McGowan – Chief Scientific Officer, Orion Biotechnology – will be presenting the results of the CHARM-03 Phase 1 microbicide study which evaluated the safety and ex vivo efficacy of the CCR5 antagonist maraviroc for HIV prevention. The study is unique because it included both oral and topical maraviroc exposure. The CHARM-03 study emphasizes the importance of CCR5 antagonists in HIV prevention and this study contributed in part, to Orion Biotechnology’s focus on their potent CCR5 antagonist (5P12 RANTES) as a microbicide candidate.

contact us

Leave  us a message and we will try to respond by the next business day

ORION Logo Pantone(375x133)

Our Headquarters

343 Preston Street

11th floor,

Ottawa, ON K1S 1N4

CANADA

info@orionbiotechnology.com

+1 343.291.1032

contact us

Leave  us a message and we will try to respond by the next business day

ORION Logo Pantone(375x133)

Our Headquarters

343 Preston Street

11th floor,

Ottawa, ON K1S 1N4

CANADA

info@orionbiotechnology.com

+1 343.291.1032